Underrepresentation of women in cardiovascular trials- it is time to shatter this glass ceiling

Area of Science:

• Cardiology
• Clinical Trials
• Health Disparities

Background:

• Cardiovascular disease (CVD) is the primary cause of death for women.
• Underrepresented minority (URM) women face the highest CVD mortality rates.
• Women, particularly URM women, have historically been underrepresented in clinical trials.

Purpose of the Study:

• To review the extent, consequences, and reasons for the underrepresentation of women in CVD trials.
• To propose a comprehensive strategy to increase female participation in these critical studies.

Main Methods:

• Systematic review of existing literature on female enrollment in CVD trials.
• Analysis of current initiatives aimed at increasing diversity in clinical research.
• Development of a multifaceted approach to address enrollment disparities.

Main Results:

• Despite increased efforts, the enrollment of women, including URM women, in CVD trials remains significantly low.
• Existing systematic reviews confirm the persistent underrepresentation of women.

Conclusions:

• The underrepresentation of women in CVD trials poses a significant barrier to improving cardiovascular health outcomes for this demographic.
• Implementing proposed multifaceted solutions is essential to enhance the inclusion of women, especially URM women, in clinical trials.
• Increased participation of diverse female populations in trials is anticipated to lead to better CVD management and treatment strategies.